135 related articles for article (PubMed ID: 27197184)
21. M-COPA, a novel Golgi system disruptor, suppresses apoptosis induced by Shiga toxin.
Hattori T; Watanabe-Takahashi M; Shiina I; Ohashi Y; Dan S; Nishikawa K; Yamori T; Naito M
Genes Cells; 2016 Aug; 21(8):901-6. PubMed ID: 27302278
[TBL] [Abstract][Full Text] [Related]
22. Significances of contactin-1 expression in human gastric cancer and knockdown of contactin-1 expression inhibits invasion and metastasis of MKN45 gastric cancer cells.
Chen DH; Yu JW; Wu JG; Wang SL; Jiang BJ
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2109-20. PubMed ID: 25952582
[TBL] [Abstract][Full Text] [Related]
23. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Takeda M; Arao T; Yokote H; Komatsu T; Yanagihara K; Sasaki H; Yamada Y; Tamura T; Fukuoka K; Kimura H; Saijo N; Nishio K
Clin Cancer Res; 2007 May; 13(10):3051-7. PubMed ID: 17505008
[TBL] [Abstract][Full Text] [Related]
24. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
Zou HY; Li Q; Lee JH; Arango ME; McDonnell SR; Yamazaki S; Koudriakova TB; Alton G; Cui JJ; Kung PP; Nambu MD; Los G; Bender SL; Mroczkowski B; Christensen JG
Cancer Res; 2007 May; 67(9):4408-17. PubMed ID: 17483355
[TBL] [Abstract][Full Text] [Related]
25. Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity.
Zhang T; Zhang L; Fan S; Zhang M; Fu H; Liu Y; Yin X; Chen H; Xie L; Zhang J; Gavine PR; Gu Y; Ni X; Su X
PLoS One; 2015; 10(7):e0134493. PubMed ID: 26217940
[TBL] [Abstract][Full Text] [Related]
26. Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors.
Ohashi Y; Okamura M; Katayama R; Fang S; Tsutsui S; Akatsuka A; Shan M; Choi HW; Fujita N; Yoshimatsu K; Shiina I; Yamori T; Dan S
Oncotarget; 2018 Jan; 9(2):1641-1655. PubMed ID: 29416720
[TBL] [Abstract][Full Text] [Related]
27. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities.
Hong SW; Jung KH; Lee HS; Son MK; Yan HH; Kang NS; Lee J; Hong SS
Carcinogenesis; 2013 Sep; 34(9):2156-69. PubMed ID: 23671132
[TBL] [Abstract][Full Text] [Related]
28. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation.
Saisana M; Griffin SM; May FE
Oncotarget; 2016 Aug; 7(34):54445-54462. PubMed ID: 27437872
[TBL] [Abstract][Full Text] [Related]
29. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy.
Musiani D; Konda JD; Pavan S; Torchiaro E; Sassi F; Noghero A; Erriquez J; Perera T; Olivero M; Di Renzo MF
FASEB J; 2014 Sep; 28(9):4055-67. PubMed ID: 24903273
[TBL] [Abstract][Full Text] [Related]
30. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
Yamaguchi H; Takanashi M; Yoshida N; Ito Y; Kamata R; Fukami K; Yanagihara K; Sakai R
Cancer Sci; 2014 May; 105(5):528-36. PubMed ID: 24612061
[TBL] [Abstract][Full Text] [Related]
31. Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer.
Takiguchi S; Inoue K; Matsusue K; Furukawa M; Teramoto N; Iguchi H
Int J Oncol; 2017 Jul; 51(1):184-192. PubMed ID: 28498406
[TBL] [Abstract][Full Text] [Related]
32. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
[TBL] [Abstract][Full Text] [Related]
33. miR-215 promotes malignant progression of gastric cancer by targeting RUNX1.
Li N; Zhang QY; Zou JL; Li ZW; Tian TT; Dong B; Liu XJ; Ge S; Zhu Y; Gao J; Shen L
Oncotarget; 2016 Jan; 7(4):4817-28. PubMed ID: 26716895
[TBL] [Abstract][Full Text] [Related]
34. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
35. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.
Sampson ER; Martin BA; Morris AE; Xie C; Schwarz EM; O'Keefe RJ; Rosier RN
J Bone Miner Res; 2011 Jun; 26(6):1283-94. PubMed ID: 21308771
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
37. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
[TBL] [Abstract][Full Text] [Related]
38. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
Cepero V; Sierra JR; Corso S; Ghiso E; Casorzo L; Perera T; Comoglio PM; Giordano S
Cancer Res; 2010 Oct; 70(19):7580-90. PubMed ID: 20841479
[TBL] [Abstract][Full Text] [Related]
39. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
40. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
Corso S; Ghiso E; Cepero V; Sierra JR; Migliore C; Bertotti A; Trusolino L; Comoglio PM; Giordano S
Mol Cancer; 2010 May; 9():121. PubMed ID: 20500904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]